Stephen Marcella
Director, Outcomes Research
Merck & Co., Inc.
2000 Galloping Hill Road
PO Box 539
Kenilworth,
NJ
USA
09033-1310
Papers:
2E-2
BEZLOTOXUMAB IS ASSOCIATED WITH A REDUCTION IN CUMULATIVE HOSPITALIZED DAYS: ANALYSIS OF THE HOSPITALIZATION DATA FROM THE MODIFY I AND II CLINICAL TRIALS
2E-5
COST-EFFECTIVENESS OF BEZLOTOXUMAB+STANDARD OF CARE (SOC) VERSUS PLACEBO+SOC FOR THE PREVENTION OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION IN THE UNITED STATES
2E-6
BUDGET IMPACT OF FIDAXOMICIN COMPARED WITH VANCOMYCIN FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA IN THE UNITED STATES